Japan
|
![]() |
|||
March - April 2005 |
In this issueThe ‘CARS 21’ Initiative and JAMA’s ContributionThe “Re-launched” Lisbon Strategy and competitivenessClean Air |
The ‘CARS 21’ Initiative and JAMA’s Contribution
Background On
JAMA’s Contribution JAMA fully supports the ‘CARS 21’ initiative and welcomes the opportunity to participate in the ‘CARS 21’ consultation and forthcoming Hearing. The development of a European automotive regulatory framework for the next ten years that creates the preconditions for a sustainable and competitive automotive sector forms a priority for JAMA and its members, who are willing to contribute to the development of this framework and welcome all initiatives enabling their participation. JAMA feels that it is important that CARS 21’s work does not reduce to a hunt for ‘poor’ regulations. JAMA shares the opinion expressed in the European Commission’s Competitiveness Report 2004 that “the regulatory environment is one of the major determinants of competitiveness” (p 266). With the authors of the Report, JAMA also recognises the difficulties in assessing the impact of regulation on competitiveness. JAMA agrees with them that one of the most important considerations to be taken into account is the complexity of the demands of society, which has led to a cumulation of regulations. JAMA believes that it is the cumulative effect of regulations, which individually may have persuasive merits but are often not mutually consistent, that present the sector with significant burdens. The JAMA contribution to the consultation will highlight the current contribution of the European subsidiaries of Japanese brands to the competitiveness of the European Motor Industry. Among other things it highlights how best practices in manufacturing, employment and training have so far enabled them to become an integral part of the European automotive sector and how JAMA is fully committed to the strengthening of the sector in the EU and globally. The key themes discussed include:
JAMA does not see its contribution to the CARS 21 initiative as an end in itself but rather as its first contribution to an evolving process. JAMA fully supports the CARS 21 initiative and is willing to contribute in a significant manner to its objectives.
|
||||